Sponsor content
17 result(s) found, displaying 11 to 17
-
Prescription medicine decision summaryTGA decision: Xembify (normal immunoglobulin human) is approved to treat primary immunodeficiency diseases (PID).
-
Australian public assessment report (AusPar)VeraSeal (human fibrinogen and human thrombin) for the supportive treatment of hemostasis.
-
Prescription medicine registrationActive ingredients: human immunoglobulin G.
-
INTRATECT 5% 1g in 20 mL human normal immunoglobulin solution for intravenous infusion vial (164550)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INTRATECT 5% 1g in 20 mL human normal immunoglobulin solution for intravenous infusion vial. -
INTRATECT 5% 5g in 100mL human normal immunoglobulin solution for intravenous infusion vial (164551)
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INTRATECT 5% 5g in 100mL human normal immunoglobulin solution for intravenous infusion vial. -
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INTRATECT 5% 2.5g in 50mL human normal immunoglobulin solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for INTRATECT 5% 10g in 200 mL human normal immunoglobulin solution for intravenous infusion vial.